463 related articles for article (PubMed ID: 31578287)
1. Clearance of Chikungunya Virus Infection in Lymphoid Tissues Is Promoted by Treatment with an Agonistic Anti-CD137 Antibody.
Hong JP; McCarthy MK; Davenport BJ; Morrison TE; Diamond MS
J Virol; 2019 Dec; 93(24):. PubMed ID: 31578287
[TBL] [Abstract][Full Text] [Related]
2. An Agonistic Anti-CD137 Antibody Disrupts Lymphoid Follicle Structure and T-Cell-Dependent Antibody Responses.
Hong JP; Reynoso GV; Andhey PS; Swain A; Turner JS; Boon ACM; Krammer F; Ellebedy AH; Zanini F; Artyomov M; Hickman HD; Diamond MS
Cell Rep Med; 2020 Jun; 1(3):. PubMed ID: 32699843
[TBL] [Abstract][Full Text] [Related]
3. Multiple immune factors are involved in controlling acute and chronic chikungunya virus infection.
Poo YS; Rudd PA; Gardner J; Wilson JA; Larcher T; Colle MA; Le TT; Nakaya HI; Warrilow D; Allcock R; Bielefeldt-Ohmann H; Schroder WA; Khromykh AA; Lopez JA; Suhrbier A
PLoS Negl Trop Dis; 2014 Dec; 8(12):e3354. PubMed ID: 25474568
[TBL] [Abstract][Full Text] [Related]
4. Chikungunya Virus Evades Antiviral CD8
Davenport BJ; Bullock C; McCarthy MK; Hawman DW; Murphy KM; Kedl RM; Diamond MS; Morrison TE
J Virol; 2020 Apr; 94(9):. PubMed ID: 32102875
[TBL] [Abstract][Full Text] [Related]
5. Chikungunya Virus Exposure Partially Cross-Protects against Mayaro Virus Infection in Mice.
Fumagalli MJ; de Souza WM; de Castro-Jorge LA; de Carvalho RVH; Castro ÍA; de Almeida LGN; Consonni SR; Zamboni DS; Figueiredo LTM
J Virol; 2021 Nov; 95(23):e0112221. PubMed ID: 34549980
[TBL] [Abstract][Full Text] [Related]
6. Chikungunya viruses that escape monoclonal antibody therapy are clinically attenuated, stable, and not purified in mosquitoes.
Pal P; Fox JM; Hawman DW; Huang YJ; Messaoudi I; Kreklywich C; Denton M; Legasse AW; Smith PP; Johnson S; Axthelm MK; Vanlandingham DL; Streblow DN; Higgs S; Morrison TE; Diamond MS
J Virol; 2014 Aug; 88(15):8213-26. PubMed ID: 24829346
[TBL] [Abstract][Full Text] [Related]
7. Chikungunya virus impairs draining lymph node function by inhibiting HEV-mediated lymphocyte recruitment.
McCarthy MK; Davenport BJ; Reynoso GV; Lucas ED; May NA; Elmore SA; Tamburini BA; Hickman HD; Morrison TE
JCI Insight; 2018 Jul; 3(13):. PubMed ID: 29997290
[TBL] [Abstract][Full Text] [Related]
8. A potent neutralizing IgM mAb targeting the N218 epitope on E2 protein protects against Chikungunya virus pathogenesis.
Lam S; Nyo M; Phuektes P; Yew CW; Tan YJ; Chu JJ
MAbs; 2015; 7(6):1178-94. PubMed ID: 26305993
[TBL] [Abstract][Full Text] [Related]
9. Chronic joint disease caused by persistent Chikungunya virus infection is controlled by the adaptive immune response.
Hawman DW; Stoermer KA; Montgomery SA; Pal P; Oko L; Diamond MS; Morrison TE
J Virol; 2013 Dec; 87(24):13878-88. PubMed ID: 24131709
[TBL] [Abstract][Full Text] [Related]
10. Pathogenic Chikungunya Virus Evades B Cell Responses to Establish Persistence.
Hawman DW; Fox JM; Ashbrook AW; May NA; Schroeder KMS; Torres RM; Crowe JE; Dermody TS; Diamond MS; Morrison TE
Cell Rep; 2016 Aug; 16(5):1326-1338. PubMed ID: 27452455
[TBL] [Abstract][Full Text] [Related]
11. A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection.
Kose N; Fox JM; Sapparapu G; Bombardi R; Tennekoon RN; de Silva AD; Elbashir SM; Theisen MA; Humphris-Narayanan E; Ciaramella G; Himansu S; Diamond MS; Crowe JE
Sci Immunol; 2019 May; 4(35):. PubMed ID: 31101672
[TBL] [Abstract][Full Text] [Related]
12. Chikungunya virus infection results in higher and persistent viral replication in aged rhesus macaques due to defects in anti-viral immunity.
Messaoudi I; Vomaske J; Totonchy T; Kreklywich CN; Haberthur K; Springgay L; Brien JD; Diamond MS; Defilippis VR; Streblow DN
PLoS Negl Trop Dis; 2013; 7(7):e2343. PubMed ID: 23936572
[TBL] [Abstract][Full Text] [Related]
13. Dermal and muscle fibroblasts and skeletal myofibers survive chikungunya virus infection and harbor persistent RNA.
Young AR; Locke MC; Cook LE; Hiller BE; Zhang R; Hedberg ML; Monte KJ; Veis DJ; Diamond MS; Lenschow DJ
PLoS Pathog; 2019 Aug; 15(8):e1007993. PubMed ID: 31465513
[TBL] [Abstract][Full Text] [Related]
14. Interferon Alpha, but Not Interferon Beta, Acts Early To Control Chronic Chikungunya Virus Pathogenesis.
Locke MC; Fox LE; Dunlap BF; Young AR; Monte K; Lenschow DJ
J Virol; 2022 Jan; 96(1):e0114321. PubMed ID: 34668781
[TBL] [Abstract][Full Text] [Related]
15. CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer.
Srivastava RM; Trivedi S; Concha-Benavente F; Gibson SP; Reeder C; Ferrone S; Ferris RL
Clin Cancer Res; 2017 Feb; 23(3):707-716. PubMed ID: 27496866
[TBL] [Abstract][Full Text] [Related]
16. A Rodent Model of Chikungunya Virus Infection in RAG1 -/- Mice, with Features of Persistence, for Vaccine Safety Evaluation.
Seymour RL; Adams AP; Leal G; Alcorn MD; Weaver SC
PLoS Negl Trop Dis; 2015; 9(6):e0003800. PubMed ID: 26115459
[TBL] [Abstract][Full Text] [Related]
17. Disease Resolution in Chikungunya-What Decides the Outcome?
Srivastava P; Kumar A; Hasan A; Mehta D; Kumar R; Sharma C; Sunil S
Front Immunol; 2020; 11():695. PubMed ID: 32411133
[TBL] [Abstract][Full Text] [Related]
18. Chikungunya Virus-Induced Arthritis: Role of Host and Viral Factors in the Pathogenesis.
Amdekar S; Parashar D; Alagarasu K
Viral Immunol; 2017 Dec; 30(10):691-702. PubMed ID: 28910194
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion.
Houot R; Goldstein MJ; Kohrt HE; Myklebust JH; Alizadeh AA; Lin JT; Irish JM; Torchia JA; Kolstad A; Chen L; Levy R
Blood; 2009 Oct; 114(16):3431-8. PubMed ID: 19641184
[TBL] [Abstract][Full Text] [Related]
20. Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy.
Yonezawa A; Dutt S; Chester C; Kim J; Kohrt HE
Clin Cancer Res; 2015 Jul; 21(14):3113-20. PubMed ID: 25908780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
